The following guide has been developed with the support of local gastroenterologists and is currently under review.
There are many causes of anaemia so please see the Anaemia page for advice on initial investigation and management.
This page is specifically intended for patients with true iron deficiency anaemia (or iron deficiency without anaemia)
You may also find the following CKS guidelines helpful:
Clinical knowledge summary guidance for the management of iron deficiency anaemia.
Initial investigation should establish if anaemia is truly due to iron deficiency.
IDA is normally suspected if the anaemia is microcytic but this is not always the case*.
Haematinics should normally be performed and ferritin is usually low in IDA. However, ferritin can be falsely raised in some conditions, so if IDA is still suspected then consider further investigations.
*It is important not to miss is an underlying iron deficiency as iron deficiency anaemia may be normocytic in some elderly patients and sometimes the ferritin is spuriously raised and so appears to be “normal”. Any inflammatory condition (such as rheumatoid disease) can falsely raise the ferritin even in the presence of iron deficiency anaemia, as can chronic kidney disease, liver disease, malignancy, hyperthyroidism and heavy alcohol intake.
To help clarify the situation, it may be worth also checking the patient’s iron status (for NBT, available on ICE as iron status under haematology panel, for UHB can request zinc protoporphyrin - ZZP). The finding of a low serum iron and/or low transferrin saturation (or raised ZPP) would point towards an iron deficiency.
Summary of investigations:
Once an iron deficiency picture has been established then further investigations should be directed according to the suspected cause.
A thorough history and examination should be undertaken and if there is no obvious focus of bleeding that could explain the anaemia (e.g. menorrhagia, recurrent epistaxis) then the following should be considered:
If there are no symptoms and examination is normal, then investigation of IDA should initially prioritise the exclusion of lower GI causes. Investigation of upper GI and other causes can then follow if required.
If iron deficiency is associated with red flags then FIT test or 2WW referral may be indicated - see Red Flag section below.
If there are red flags and malignancy is suspected then please consider the following 2WW guidelines:
Lower GI 2WW guidlines - includes advice on when to undertake a FIT test.
If a 2WW referral is not indicated then consider referral for lower GI endoscopy initially via eRS direct to test.
If lower GI investigations are normal then consider upper GI endoscopy via eRS direct to test.
If a GI cause for iron deficiency anaemia is not apparent from initial upper and lower GI investigations or a patient is not suitable for direct to test, then please consider the following before referral:
In all patients, consider oral iron supplements which can be started prior to endoscopy (although if 2ww colonoscopy is requested it would be best to advise patient to not start taking the iron until the colonoscopy has been performed, but they can be given the prescription).
Monitor Hb and if it drops again or fails to increment adequately with oral iron then refer to secondary care for consideration of small bowel investigation.
If referral is indicated, then please refer to gastroenterology via eRS (UHBW or NBT) initially where a decision on further investigation can be made (including onward referral for capsule endoscopy if this is necessary).
If you are uncertain about appropriateness of referral, then consider requesting gastroenterology A and G.
Further investigation
For iron-deficient anaemia, small bowel investigation is only indicated for cases that fail to correct with iron replacement (or maybe need transfusion), or sometimes when there is recurrent IDA. This is because the pathology yield from small bowel investigation is relatively low.
Proceeding directly to small bowel investigations is only indicated when there is ongoing Melaena with normal investigations – these patients tend to be under secondary care already.
The above advice is based on BSG guidelines (1) with local guidance provided by Dr Ana Terlovich (Consultant gastroenterologist at NBT).
Oral iron supplements can be usually be started while awaiting investigation (although if 2ww colonoscopy is requested it would be best to advise patient to not start taking the iron until the colonoscopy has been performed).
In patients who do not tolerate oral iron or do not respond to oral iron supplements then an iron infusion may be considered.
Please see the Pathology page on Remedy for advice on services available at UHBW and NBT and how to refer.
The British Society of Gastroenterology Guidelines on Management of IDA (2011) has advice on how to manage patients with low iron and normal Hb as well as iron deficiency anaemia - summary as below:
'Iron deficiency without anaemia is three times as common as IDA, but there is no consensus on whether these patients should be investigated, and further research is needed. The largest study shows very low prevalence of GI malignancy in patients with iron deficiency alone (0.9% of postmenopausal women and men, and 0% of premenopausal women)(2). Higher rates have been reported only in more selected groups. In the absence of firm evidence, we tentatively recommend coeliac serology in all these patients but that other investigation be reserved for those with higher-risk profiles (eg, age >50 years) after discussion of the risks and potential benefits of upper and lower GI investigation. All others should be treated empirically with oral iron replacement for 3 months and investigated if iron deficiency recurs within the next 12 months.
(2) Ioannou GN, Rockey DC, Bryson CL, et al. Iron deficiency and gastrointestinal malignancy: a population-based cohort study. Am J Med 2002;113:276e80.'
Efforts are made to ensure the accuracy and agreement of these guidelines, including any content uploaded, referred to or linked to from the system. However, BNSSG ICB cannot guarantee this. This guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, in accordance with the mental capacity act, and informed by the summary of product characteristics of any drugs they are considering. Practitioners are required to perform their duties in accordance with the law and their regulators and nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Information provided through Remedy is continually updated so please be aware any printed copies may quickly become out of date.